In the latest session, Medifast Inc (NYSE: MED) closed at $34.57 down -3.30% from its previous closing price of $35.75. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 590629 shares were traded.
Ratios:
For a deeper understanding of Medifast Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 2.43. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on October 13, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $82.
On November 04, 2022, DA Davidson Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $278 to $106.
Jefferies Downgraded its Buy to Hold on August 04, 2022, whereas the target price for the stock was revised from $345 to $150.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 08 ’24 when SCHLACKMAN SCOTT sold 4,053 shares for $39.44 per share. The transaction valued at 159,866 led to the insider holds 7,785 shares of the business.
BROWN JEFFREY J bought 58 shares of MED for $4,020 on Nov 07 ’23. The Director now owns 5,784 shares after completing the transaction at $68.89 per share. On Nov 07 ’23, another insider, SCHLACKMAN SCOTT, who serves as the Director of the company, bought 53 shares for $68.89 each. As a result, the insider paid 3,627 and bolstered with 10,538 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MED now has a Market Capitalization of 376.66M and an Enterprise Value of 248.63M. As of this moment, Medifast’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.80, and their Forward P/E ratio for the next fiscal year is 11.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35 while its Price-to-Book (P/B) ratio in mrq is 1.87. Its current Enterprise Value per Revenue stands at 0.23 whereas that against EBITDA is 1.78.
Stock Price History:
Over the past 52 weeks, MED has reached a high of $109.52, while it has fallen to a 52-week low of $35.63. The 50-Day Moving Average of the stock is 50.44, while the 200-Day Moving Average is calculated to be 72.52.
Shares Statistics:
For the past three months, MED has traded an average of 334.62K shares per day and 391k over the past ten days. A total of 10.90M shares are outstanding, with a floating share count of 10.65M. Insiders hold about 2.21% of the company’s shares, while institutions hold 96.23% stake in the company. Shares short for MED as of Feb 29, 2024 were 1.94M with a Short Ratio of 5.79, compared to 1.92M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.78% and a Short% of Float of 27.01%.
Dividends & Splits
According to the company, the forward annual dividend rate for MED is 4.95, from 4.95 in the trailing year. Against a Trailing Annual Dividend Yield of 13.85%, it implies a Forward Annual Dividend Yield of 19.09%. The stock’s 5-year Average Dividend Yield is 4.32.
Earnings Estimates
There are 2 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.78 for the current quarter, with a high estimate of $0.82 and a low estimate of $0.74, while EPS last year was $3.67. The consensus estimate for the next quarter is $0.67, with high estimates of $0.87 and low estimates of $0.46.
Analysts are recommending an EPS of between $1.95 and $1.86 for the fiscal current year, implying an average EPS of $1.9. EPS for the following year is $3.13, with 2 analysts recommending between $3.65 and $2.62.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $168.9M this quarter.It ranges from a high estimate of $172.4M to a low estimate of $165.4M. As of the current estimate, Medifast Inc’s year-ago sales were $348.98M, an estimated decrease of -51.60% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $175.1M, a decrease of -40.90% over than the figure of -$51.60% in the same quarter last year. There is a high estimate of $194.6M for the next quarter, whereas the lowest estimate is $155.6M.
A total of 2 analysts have provided revenue estimates for MED’s current fiscal year. The highest revenue estimate was $730.4M, while the lowest revenue estimate was $658.3M, resulting in an average revenue estimate of $694.35M. In the same quarter a year ago, actual revenue was $1.07B, down -35.20% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $755.75M in the next fiscal year. The high estimate is $767M and the low estimate is $744.5M. The average revenue growth estimate for next year is up 8.80% from the average revenue estimate for this year.
